# DAD-IO (NCT04724018)

> Sacituzumab Govitecan Plus EV in Metastatic UC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04724018
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder Cancer
- Interventions: Sacituzumab Govitecan (SG); Enfortumab vedotin-ejfv (EV); Pembrolizumab
- Enrollment: 106
- Primary outcome: Maximum Tolerated Dose (MTD) of Sacituzumab Govitecan (SG) and Enfortumab vedotin-ejfv (EV) in Combination
- Primary outcome: Dose-limiting toxicity (DLT) of Sacituzumab Govitecan (SG) and Enfortumab Vedotin in combination
- Primary outcome: Efficacy of Sacituzumab Govitecan (SG) and Enfortumab Vedotin in combination
- Primary outcome: Efficacy of Sacituzumab Govitecan (SG) and Enfortumab Vedotin and Pembrolizumab in combination

## Indexed commentary on DAD-IO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 20
- YouTube: 7
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dad-io-nct04724018

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04724018", "email": "<work email>"}; the inbox owner confirms by the emailed link.